Regeneron Pharmaceuticals Inc.’s (REGN) investigational triple antibody cocktail treatment for Ebola virus infection, REGN-EB3, is under priority review by the FDA, with a decision expected on October 25, 2020.REGN-EB3 has received Orphan Drug and Breakthrough Therapy designation from the FDA. This compound is being developed under an ongoing collaboration and with funding provided by the Biomedical Advanced Research and Development Authority (BARDA).In clinical trials, REGN-EB3 has demonstrated superiority over Mapp Biopharmaceutical’s investigational triple monoclonal antibody ZMapp in reducing mortality from Ebola virus disease.There are no FDA-approved antiviral drugs to treat EVD in people. However, there is a licensed vaccine for the prevention of Ebola virus disease, Merck’s Ervebo that was approved last December.REGN closed Friday’s (Sep.25, 2020) trading at $574.06, up 2.98%.